Instrument Inactif

Communiqués LogicBio Therapeutics, Inc.

Actions

LOGC

US54142F1021

Produits pharmaceutiques

Communiqués

17/11/22	Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics	AQ
16/11/22	LOGICBIO THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	LogicBio Therapeutics : Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction - Form 8-K	PU
14/11/22	LOGICBIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/11/22	LOGICBIO THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
14/11/22	LogicBio Therapeutics: Q3 Earnings Snapshot	AQ
14/11/22	LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates	PR
20/10/22	LOGICBIO THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
19/10/22	LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC	BU
07/10/22	LOGICBIO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
04/10/22	LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC	BU
04/10/22	Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine	AQ
03/10/22	LOGICBIO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
03/10/22	Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine	PR
23/09/22	LOGICBIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
21/09/22	LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE	PR
20/09/22	LOGICBIO THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
16/09/22	LOGICBIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
16/08/22	LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update	AQ
15/08/22	LogicBio Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K	PU
15/08/22	LOGICBIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
15/08/22	LogicBio Therapeutics: Q2 Earnings Snapshot	AQ
21/06/22	LOGICBIO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
23/05/22	LogicBio Therapeutics : ASGCT 2022 - Analytical development	PU
18/05/22	LogicBio Therapeutics to Present at H.C. Wainwright Global Investment Conference	AQ